Paul Rose - Henry Schein Senior Vice President Global Supply Chain
| HSIC Stock | USD 73.21 0.45 0.62% |
President
Mr. Paul Rose serves as Senior Vice President Global Supply Chain of the Company. He is also a member of our Executive Management Committee. Prior to holding his current position, Mr. Rose held a number of key roles with increasing responsibility throughout the Company, including serving as Vice President, Global Supply Chain from 2008 to 2013, Vice President, Global Inventory Management from 2004 to 2008 and Vice President, Inventory Management, North America from 2001 to 2004. As Senior Vice President of Global Supply Chain, Mr. Rose is directly responsible for distribution, inventory and product mix to support the Companys Global Dental, Medical, Animal Health and Lab businesses. Mr. Roses team generates over 7 billion in product purchases each year and maintains a robust level of inventory that enables the Company to service its customers with product fill rates of over 98 percent on a global basis. He is also responsible for working with the Companys senior management team to establish and implement Worldwide Supply Chain procedures and guidelines. In addition to his Global Supply Chain responsibilities, he manages the Companys Inventory Management team, which includes Purchasing and Product Data Management since 2013.
| Age | 59 |
| Tenure | 11 years |
| Address | 135 Duryea Road, Melville, NY, United States, 11747 |
| Phone | 631 843 5500 |
| Web | https://www.henryschein.com |
Henry Schein Management Efficiency
The company has return on total asset (ROA) of 0.0453 % which means that it generated a profit of $0.0453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0888 %, meaning that it created $0.0888 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to 0.07. In addition to that, Return On Capital Employed is expected to decline to 0.10. At present, Henry Schein's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 219.4 M, whereas Total Current Assets are forecasted to decline to about 2.4 B.Similar Executives
| Found 6 records | PRESIDENT Age | ||
| David Mogill | Zynex Inc | N/A | |
| Christopher Brown | Zynex Inc | N/A | |
| JeanFrancois Bachelard | EDAP TMS SA | 60 | |
| Donald Gregg | Zynex Inc | N/A | |
| Frederic Pech | EDAP TMS SA | 55 | |
| Rick Luckenbill | Zynex Inc | N/A | |
Management Performance
| Return On Equity | 0.0888 | ||||
| Return On Asset | 0.0453 |
Henry Schein Leadership Team
Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Ettinger, Senior Vice President - Corporate and Legal Affairs, Secretary | ||
| David McKinley, President Medical Group | ||
| Paul Rose, Senior Vice President Global Supply Chain | ||
| Norman Matthews, Independent Director | ||
| Philip Laskawy, Lead Independent Director | ||
| Steven Paladino, CFO, Executive VP and Executive Director | ||
| Ronald South, Senior CFO | ||
| Barry Alperin, Independent Director | ||
| Brad Connett, President - Henry Schein'sU.S. Medical Group | ||
| Shira Goodman, Independent Director | ||
| Lorelei McGlynn, Senior Vice President - Global Human Resources and Financial Operations | ||
| Bradley Sheares, Independent Director | ||
| Leonard David, Chief Compliance Officer, Senior Vice President | ||
| James Harding, CTO, Senior Vice President | ||
| Paul Brons, Independent Director | ||
| Lonnie Shoff, President and CEO of Global Animal Health and Strategic Partnerships Group | ||
| Gerald Benjamin, Chief Admin. Officer, Executive VP and Director | ||
| Bob Minowitz, President International Dental Group | ||
| Dianne Rekow, Director | ||
| Anne Margulies, Independent Director | ||
| Stanley Komaroff, Sr. Advisor | ||
| Mark Mlotek, Chief Strategic Officer, Executive VP and Director | ||
| Peter McCarthy, President - Global Animal Health Group | ||
| Bridget Ross, President of Global Medical Group | ||
| Kurt Kuehn, Independent Director | ||
| Christopher Pendergast, Senior Vice President CTO | ||
| James Breslawski, President, Executive Director and CEO of Global Dental Group | ||
| Elizabeth Rekow, Independent Director | ||
| Walter Siegel, Senior Vice President General Counsel | ||
| Graham Stanley, VP Officer | ||
| Jonathan Koch, Senior Vice President and CEO, Global Dental Group | ||
| Stanley Bergman, Executive Chairman and CEO | ||
| Joseph Herring, Independent Director | ||
| Olga Timoshkina, Chief Finance | ||
| Karen Prange, Executive Vice President; CEO of Global Animal Health, Medical and Dental Surgical Group | ||
| Carolynne Borders, Vice President - Investor Relations | ||
| Michael Racioppi, Senior Vice President Chief Merchandising Officer | ||
| Donald Kabat, Independent Director | ||
| Lawrence Bacow, Director | ||
| Louis Sullivan, Independent Director | ||
| Bradford Connett, Chief Group | ||
| Carol Raphael, Independent Director |
Henry Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0888 | ||||
| Return On Asset | 0.0453 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 13.42 B | ||||
| Shares Outstanding | 128.48 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 5.5 M | ||||
| Price To Earning | 17.39 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Henry Stock refer to our How to Trade Henry Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Henry Stock analysis
When running Henry Schein's price analysis, check to measure Henry Schein's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Henry Schein is operating at the current time. Most of Henry Schein's value examination focuses on studying past and present price action to predict the probability of Henry Schein's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Henry Schein's price. Additionally, you may evaluate how the addition of Henry Schein to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stocks Directory Find actively traded stocks across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Henry Schein's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Henry Schein. If investors know Henry will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Henry Schein listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share 3.16 | Revenue Per Share 94.466 | Quarterly Revenue Growth (0.10) | Return On Assets 0.0453 |
The market value of Henry Schein is measured differently than its book value, which is the value of Henry that is recorded on the company's balance sheet. Investors also form their own opinion of Henry Schein's value that differs from its market value or its book value, called intrinsic value, which is Henry Schein's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Henry Schein's market value can be influenced by many factors that don't directly affect Henry Schein's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Henry Schein's value and its price as these two are different measures arrived at by different means. Investors typically determine if Henry Schein is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Henry Schein's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.